RecruitingNot ApplicableNCT06286657

Xanthohumol and Viral Infections (XL)

Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans

Sponsor

University of Vienna

Enrollment

100 participants

Start Date

Aug 1, 2023

Study Type

INTERVENTIONAL

Conditions

Infection Viral

Summary

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Xanthohumol for people with infection viral. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTXanthohumol

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

DIETARY_SUPPLEMENTPlacebo

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Locations(1)

University of Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06286657

Related Trials

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

NCT071106366 locations

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

NCT061788223 locations

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

NCT038183341 location